Helix BioPharma's stock has shown some movement this week amidst various corporate updates.
Helix BioPharma Corp. (HBP.TO) experienced a modest gain of 3.57% over the past week, closing at C$1.17. Despite this uptick, the stock remains down 39.58% year-to-date. The company has recently made headlines with its financial filings and capital-raising efforts, which may be influencing investor sentiment.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$110.75M
52W high
$5.40
52W low
$1.10
1W change
+3.57%
Beta
-0.27
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 72.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+72.4% Upside
Current Price
C$1.45
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
77.8%
Annualized
90-Day Vol
56.9%
Annualized
Trend (90d)
+36.3%
Annualized drift
90d Mean
C$1.65
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.51 | C$1.16 – C$1.98 |
| 60 trading days | C$1.58 | C$1.08 – C$2.31 |
| 90 trading days | C$1.65 | C$1.04 – C$2.63 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: While Helix BioPharma's stock has shown slight recovery this week, the overall downward trend year-to-date and significant losses over the past month warrant careful consideration for investors. Understanding the company's financial health and upcoming plans may provide further clarity.
C$1.17 Closing Price, Down 39.58% YTD
Helix BioPharma's stock is trading at C$1.17, which is significantly lower than its 52-week high of C$5.40.
Bull case
The recent agreement with Kerentech Consulting Ltd. could provide Helix BioPharma with essential funds to advance its therapeutic programs. This financial boost may help position the company for future growth.
Bear case
However, with a significant net loss reported for the fiscal year and a declining stock price, investors may be cautious about the company's financial stability and its ability to execute its strategic plans.
Recent Price Action
Helix BioPharma Corp. (HBP.TO) closed at C$1.17 on the latest trading day, marking a 3.57% increase over the past week. Despite this weekly gain, the stock has faced a 26.40% decline over the last month and is down 39.58% year-to-date.
Company News and Catalysts
Advertisement
Helix BioPharma has recently filed interim financial statements for the nine-month period ending April 30, 2025, and has signed a capital-raising agreement with Kerentech Consulting Ltd. for a bridge financing round of USD 13 million aimed at advancing its therapeutic programs. These developments may be aimed at bolstering the company's financial position and supporting ongoing clinical studies.
Technical Picture
The technical indicators for Helix BioPharma show that the stock is currently trading below both its 50-day moving average (C$1.64) and its 200-day moving average (C$1.82), indicating a bearish trend. The stock has a 52-week range of C$1.10 to C$5.40, with the current price being only 2% of that range. The beta of -0.27 suggests that the stock is less volatile than the market.
Insider Activity
No recent insider activity has been reported for Helix BioPharma Corp.
Price Action Summary
As of the last close, Helix BioPharma's stock stands at C$1.17, reflecting a stable position in light of recent corporate announcements.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
